TICKERNERD
Menu
ARAYARAYHealthcare · Medical Devices

ARAY Stock Forecast: Accuray, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$0.24
−3.44% on the day

The 1 Wall Street analysts covering Accuray, Inc. hold a median 12-month price target of $0.35 — +45.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$31.1M
Ticker Nerd rank
33 / 100
Median analyst target
$0.35
Analysts covering
1
Revenue$100.9M−20.9% y/y
Operating income$6.3M
Net income−$1.9M
Free cash flow$1.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.6%
1M
−7.2%
YTD
−70.6%
1Y
−85.6%
From 52W high
−87.0%
From 52W low
+9.7%
$0.22
$1.85
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ARAY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Accuray, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
33 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
86
Accruals
85
Value
79
Quality
48
Revisions
25
Volatility
24
Issuance
23
Growth
19
Momentum
15

Size (86): Smaller than most of the companies we track.

Momentum (15): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ARAY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARAY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$0.50$1.00$1.50$2.00Jan 26Apr 26Jul 26Oct 26ARAYHigh $0.35Median $0.35Low $0.35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Low $0.35Median $0.35High $0.35

The green dot is the last close — the median target sits +45.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 May 2026JefferiesDowngradeHold$3.50 → $0.35
7 May 2026BTIGDowngradeNeutral—
5 Feb 2026BTIGMaintainsBuy—
6 Nov 2025BTIGMaintainsBuy—
14 Aug 2025BTIGMaintainsBuy—
13 Feb 2024Roth MKMInitiatesBuy—
4 Oct 2023B. Riley SecuritiesReiteratesBuy—
31 Aug 2022B. Riley SecuritiesInitiatesBuy—
24 June 2022BTIGMaintainsBuy—
23 June 2022B. Riley SecuritiesInitiatesBuy—
22 Dec 2021Loop CapitalInitiatesBuy—
21 Jan 2020BTIGUpgradeBuy—
21 Jan 2020BTIG ResearchUpgradeBuy—
1 Nov 2018CitigroupUpgradeNeutral—
17 Aug 2018CitigroupMaintainsSell—
19 Dec 2017JP MorganDowngradeUnderweight—
13 Dec 2017JP MorganDowngradeUnderweight—
30 Nov 2017Lake StreetInitiatesBuy—
23 Aug 2017JefferiesMaintainsBuy—
6 Feb 2017Aegis CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARAY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ARAY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Accuray, Inc. returned −85.6% against +16.2% for the S&P 500, dividends included.

ARAY vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26ARAYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ARAY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Accuray, Inc. (ARAY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.7×

Cheaper than 81% of US stocks

Price / sales
0.1×

Cheaper than 97% of US stocks

Price / book
0.7×

Cheaper than 79% of US stocks

EV / EBITDA
−49.5×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
−20.9%

Higher than 11% of US stocks

Earnings growth (YoY)
−20.9%

Higher than 20% of US stocks

Gross margin
34.8%

Higher than 42% of US stocks

Operating margin
6.2%

Higher than 57% of US stocks

Net margin
−12.2%

Higher than 18% of US stocks

Returns & dividend
Return on equity
−80.1%

Higher than 16% of US stocks

Return on assets
−1.4%

Higher than 39% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Accuray, Inc. (ARAY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Accuray, Inc. has a market value of $31.1M and an enterprise value of $174.5M.

  • Revenue in the twelve months to 30 June 2026: $401.9M. The latest quarter shrank 20.9% year on year.

  • Net income over the same four quarters: −$49.2M, a −12.2% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.40.

  • Free cash flow in the twelve months to 30 June 2026: −$19.3M, after $6.4M of capital spending.

  • Shares outstanding: 119.4M.

  • Trailing P/E: −0.7×; forward P/E: −1.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Accuray, Inc. employs 809 people — $497K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

ARAY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ARAYAccuray, Inc.$31.1M
33
ITOCiTonic Holdings Ltd.$29.4M
18
NSYSNortech Systems, Inc.$31.5M
81
BDMDBaird Medical Investment Holdings Ltd.$25.3M
22
MODDModular Medical, Inc.$25.3M
14
PMIPicard Medical, Inc.$22.6M
24
NSPRInspireMD, Inc.$22.5M
50

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Accuray, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ARAY news & analysis

Accuray Announces Stockholder Approval of Key Financing-Related Proposals and Appointment of New Independent Director

PRNewsWire · 6 Oct 2026positive

Accuray said stockholders approved all proposals at its October 6 special meeting, enabling the company to complete previously announced transactions with TCW Asset Management Company, its primary lender and largest shareholder.

Why it matters — The approvals clear a stated step toward completing the TCW transactions, which are relevant to Accuray's financing.

Accuray and Samsung NeuroLogica Advance Volumetric Imaging Collaboration for the Accuray CyberKnife® Platform

PRNewsWire · 27 Sept 2026positive

Accuray announced it has entered into agreements with Samsung HME America, Inc., dba NeuroLogica Corp., to pursue advanced volumetric imaging capabilities for its CyberKnife System. The collaboration is intended to advance imaging technology for the platform.

Why it matters — An ARAY watcher would care because enhancing the CyberKnife System's imaging capabilities could strengthen the product's competitive functionality in radiation therapy.

Accuray and RaySearch Agree to Collaboration Integrating RayStation Software with Accuray Platforms to Accelerate Accuray's Online Adaptive Capabilities

PRNewsWire · 11 Sept 2026positive

Accuray and RaySearch Laboratories announced a definitive agreement for an expanded collaboration to integrate RayStation software with Accuray platforms, aimed at accelerating Accuray's adoption of online adaptive radiation therapy.

Why it matters — ARAY watchers would care because this partnership could strengthen Accuray's radiation therapy product capabilities through accelerated online adaptive technology integration.

Accuray Incorporated (ARAY) Q4 2026 Earnings Call Transcript

Seeking Alpha · 19 Aug 2026neutral

Seeking Alpha published the transcript of Accuray Incorporated's (ARAY) fourth-quarter fiscal 2026 earnings call. The item reports the availability of the call transcript, which covers the company's quarterly results and management commentary.

Why it matters — An ARAY watcher would want to review this transcript for the company's latest quarterly financial results and management's discussion of its performance.

Accuray Reports Fourth Quarter and Fiscal 2026 Financial Results

PRNewsWire · 19 Aug 2026neutral

Accuray Incorporated reported its financial results for the fourth quarter and fiscal 2026, which ended June 30, 2026. The announcement was made on August 19, 2026, from the company's headquarters in Madison, Wisconsin.

Why it matters — This quarterly earnings report provides ARAY watchers with an update on the company's financial performance for the recently completed fiscal year.

FAQ

Frequently asked questions about ARAY stock

What is the ARAY stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Accuray, Inc. have a median 12-month price target of $0.35, with estimates ranging from $0.35 to $0.35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARAY stock a buy right now?

Of the 1 analysts covering Accuray, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Accuray, Inc. 33 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARAY?

As at 8 Oct 2026, Accuray, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).

Will ARAY stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +45.0% from the last close, and Ticker Nerd's factor model ranks Accuray, Inc. 33 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARAY stock forecast for 2030?

No analyst covering Accuray, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARAY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.35 to $0.35 over the next 12 months.

How has ARAY stock performed over the past year?

Accuray, Inc. returned -85.6% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Accuray, Inc. do?

Accuray Incorporated is a medical device company that develops, manufactures, sells, and supports advanced radiation therapy systems for cancer treatment. The company’s portfolio centers on the CyberKnife and Radixact platforms, which are designed to deliver precise, image-guided treatments for tumors and other complex clinical cases.

What is the latest news on ARAY?

The most recent item we track (PRNewsWire, 6 Oct 2026): "Accuray Announces Stockholder Approval of Key Financing-Related Proposals and Appointment of New Independent Director". Accuray said stockholders approved all proposals at its October 6 special meeting, enabling the company to complete previously announced transactions with TCW Asset Management Company, its primary lender and largest shareholder.

Company

About Accuray, Inc.

Accuray Incorporated is a medical device company that develops, manufactures, sells, and supports advanced radiation therapy systems for cancer treatment. The company’s portfolio centers on the CyberKnife and Radixact platforms, which are designed to deliver precise, image-guided treatments for tumors and other complex clinical cases. Accuray also provides treatment planning software, motion management tools, and service offerings that support hospitals, cancer centers, and academic medical institutions. Its products are used across radiation oncology, stereotactic radiosurgery, and other specialized treatment workflows, giving the company a role in the broader market for precision oncology technologies. Accuray Incorporated focuses on combining hardware, software, and clinical support to help healthcare providers deliver targeted radiation therapy with greater accuracy and flexibility.

CEO Mr. Stephen R. LaNeve MBA · 809 employees · United States · https://www.accuray.com